BloodBrain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder

Drugs and Aging

Volumn 29, Issue 4, 2012, Pages 259-273

  Chancellor, Michael B ^a   Staskin, David R ^b   Kay, Gary G ^c   Sandage, Bobby W ^d   Oefelein, Michael G ^e   Tsao, Jack W ^f  

^a OAKLAND UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Coronado Biosciences Inc ^*  (United States)

^e ALLERGAN INC   (United States)

^f Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Adverse drug reactions; Blood brain barrier; Cholinergic receptor antagonists; CNS; Darifenacin; Elderly; Fesoterodine; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium chloride.

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ RECEPTOR AGONIST; CETIRIZINE; CYCLOSPORIN A; DARIFENACIN; FESOTERODINE; FEXOFENADINE; LANSOPRAZOLE; LOPERAMIDE; LORATADINE; MUSCARINIC M1 RECEPTOR; OMEPRAZOLE; ORPHENADRINE; OXYBUTYNIN; PLACEBO; PROPIVERINE; SIMVASTATIN; SOLIFENACIN; TOLTERODINE; TRIHEXYPHENIDYL; TROSPIUM CHLORIDE; VERAPAMIL; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ACTIVE TRANSPORT; AGING; ALERTNESS; ALZHEIMER DISEASE; ANXIETY; ASTHENIA; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; COGNITION; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIZZINESS; DRIVING ABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RECEPTOR BINDING; EMBASE; EPILEPSY; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LEARNING; LIPOPHILICITY; MEDLINE; MEMORY DISORDER; MENINGITIS; META ANALYSIS (TOPIC); MIGRAINE; MOLECULAR WEIGHT; MOTOR COORDINATION; MULTICENTER STUDY (TOPIC); MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NERVOUSNESS; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; POLYPHARMACY; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); VISUAL ORIENTATION; WORKING MEMORY; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; PERMEABILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CHOLINERGIC ANTAGONISTS; HUMANS; PERMEABILITY; PHYSICOCHEMICAL PROCESSES; URINARY BLADDER, OVERACTIVE;

EID: 84859474875     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11597530-000000000-00000     Document Type: Review

References (107)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327-36 (Pubitemid 44175300)
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 Dec; 50 (6): 1306-14; discussion 14-5
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 Jan; 61 (1): 37-49 (Pubitemid 36151708)
4. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med 2006 Mar; 119 (3 Suppl. 1): 3-8
5. Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001 Oct-Dec; 21 (5-6): 243-8
6. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 Feb 19; 350 (8): 786-99 (Pubitemid 38209648)
7. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 Sep; 54 (3): 543-62
8. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 Jul; 148 (5): 565-78 (Pubitemid 43993048)
9. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002 Aug; 366 (2): 97-103 (Pubitemid 34762267)
10. Napier C, Gupta P. Darifenacin is selective for the human recombinant M2 receptor subtype [abstract no. 445]. Presented at the 32nd Annual Meeting of the International Continence Society (ICS); 2002 Aug 28-30; Heidelberg
11. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008 Apr; 101 (8): 1036-42 (Pubitemid 351422555)
12. Heading CE. YM-905. Curr Opin CPNS Investig Drugs 2000; 2 (3): 321-5
13. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006 Feb; 147 Suppl. 2: S80-7
14. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005 Sep; 23 (4): 248-52
15. Klausner AP, Steers WD. Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep 2007 Nov; 8 (6): 441-7 (Pubitemid 350144521)
16. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 Jan; 7 (1): 41-53 (Pubitemid 41828930)
17. Grant GA, Abbott NJ, Janigro D. Understanding the physiology of the blood-brain barrier: in vitro models. News Physiol Sci 1998 Dec; 13: 287-93
18. Francis K, van Beek J, Canova C, et al. Innate immunity and brain inflammation: the key role of complement. Expert Rev Mol Med 2003 May; 5 (15): 1-19
19. Madersbacher HG. Confusion about measuring central nervous system effects. Curr Urol Rep 2004 Dec; 5 (6): 442-6
20. Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005 Dec; 53 (12): 2195-201 (Pubitemid 43001205)
21. Miulli D. Fluid management: the blood-brain barrier and intravenous fluids. In: Siddiqi J, editor. Neurosurgical intensive care. New York (NY): Thieme, 2008: 295-312
22. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003; 43: 629-56 (Pubitemid 37372656)
23. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and metaanalysis. Neurobiol Aging 2009 Mar; 30 (3): 337-52
24. Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23 (6): 395-404 (Pubitemid 36724158)
25. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001 Jun; 41 (6): 636-44 (Pubitemid 32493358)
26. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005 Feb; 27 (2): 144-53 (Pubitemid 40462007)
27. Wolters Kluwer Pharma Solutions. Source Lx Managed Care Database. 2010
28. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998 Jan; 46 (1): 8-13 (Pubitemid 28037667)
29. Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract 87]. Presented at the International Continence Society 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch
30. Sloane PD, Zimmerman S, Brown LC, et al. Inappropriate medication prescribing in residential care/assisted living facilities. J Am Geriatr Soc 2002 Jun; 50 (6): 1001-11 (Pubitemid 34666304)
31. Lau DT, Kasper JD, Potter DE, et al. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res 2004 Oct; 39 (5): 1257-76 (Pubitemid 39318923)
32. Rigler SK, Jachna CM, Perera S, et al. Patterns of potentially inappropriate medication use across three cohorts of older Medicaid recipients. Ann Pharmacother 2005 Jul-Aug; 39 (7-8): 1175-81 (Pubitemid 40943165)
33. Howard M, Dolovich L, Kaczorowski J, et al. Prescribing of potentially inappropriate medications to elderly people. Fam Pract 2004 Jun; 21 (3): 244-7 (Pubitemid 38765297)
34. Gray SL, Hedrick SC, Rhinard EE, et al. Potentially inappropriate medication use in community residential care facilities. Ann Pharmacother 2003 Jul-Aug; 37 (7-8): 988-93 (Pubitemid 36875226)
35. Roughead EE, Anderson B, Gilbert AL. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 2007 Jun; 37 (6): 402-5
36. Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005 Mar 16; 293 (11): 1348-58 (Pubitemid 40381487)
37. Barton C, Sklenicka J, Sayegh P, et al. Contraindicated medication use among patients in a memory disorders clinic.AmJ Geriatr Pharmacother 2008 Aug; 6 (3): 147-52
38. Raivio MM, Laurila JV, Strandberg TE, et al. Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging 2006; 23 (4): 333-43 (Pubitemid 43830664)
39. Cornford EM, Hyman S. Blood-brain barrier permeability to small and large molecules. Adv Drug Deliv Rev 1999 Apr 5; 36 (2-3): 145-63 (Pubitemid 29121969)
40. Liu X, Smith BJ, Chen C, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2005 Jun; 313 (3): 1254-62 (Pubitemid 40727030)
41. Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011 Mar 11; 72 (2): 235-46
42. Maruyama S, Tsukada H, Yamada S. In vivo analysis of brain muscarinic receptor occupancy after oral oxybutynin in conscious rhesus monkey by using positron emission tomography (PET) [abstract]. Neurourol Urodynam 2007; 26: 703
43. Pahlman I, d'Argy R, Nilvebrant L. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 2001 Feb; 51 (2): 125-33 (Pubitemid 32176245)
44. Devineni D, Skerjanec A, Woodworth TG. Low central nervous system (CNS) penetration by darifenacin in rats [abstract]. AAPS J 2005; 7: T2277
45. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect onmemory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010 Aug; 64 (9): 1294-300
46. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003 Dec; 4 (6): 436-40
47. Sandage B, LerchG, LarsenG, et al. Trospiumchloride does not cross the blood-brain barrier of male Long Evans rats [poster P01.174 ]. Neurology 2009; 72 (11 Suppl. 3): A50
48. Enablex (darifenacin extended-release tablets): US prescribing information. Rockaway (NJ): Warner Chilcott (US) LLC, 2010
49. Steers WD. Darifenacin: pharmacology and clinical usage. Urol Clin North Am 2006 Nov; 33 (4): 475-82, viii (Pubitemid 44441526)
50. Toviaz (fesoterodine fumarate): US prescribing information. New York (NY): Pfizer Inc., 2010
51. Malhotra B, Wood N, Sachse R, et al. Lipophilicity of 5-hydroxymethyl tolterodine, the active metabolite of fesoterodine [abstract]. Uro Today Int J 2008 Jun; 1 Suppl.: doi:10.3834/uij.1939-4810.2008.06.35
52. Ditropan XL (oxybutynin chloride) extended release tablets: US prescribing information. Raritan (NJ): Ortho- McNeil-Janssen Pharmaceuticals Inc., 2009
53. Gamble T, Sand P. Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. Patient Prefer Adherence 2008; 2: 349-56
54. VESIcare (solifenacin succinate) tablets: US prescribing information. Deerfield (IL): Astellas Pharma US, Inc.; Research Triangle Park (NC): GlaxoSmithKline, 2010
55. Maniscalco M, Singh-Franco D, Wolowich WR, et al. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006 Sep; 28 (9): 1247-72 (Pubitemid 44585291)
56. Detrol LA (tolterodine tartrate) extended release capsules: US prescribing information. New York (NY): Pfizer Inc., 2009
57. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001 Oct; 2 (10): 1685-701 (Pubitemid 33026051)
58. Sanctura XR (trospium chloride extended release capsules): US prescribing information. Irvine (CA): Allergan, Inc., 2008
59. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44 (7): 701-20 (Pubitemid 40994080)
60. Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 2006 Nov; 374 (2): 79-85 (Pubitemid 44657614)
61. Maruyama S, Tsukada H, Nishiyama S, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008 Jun; 325 (3): 774-81 (Pubitemid 351724337)
62. Gulsun M, Pinar M, Sabanci U. Psychotic disorder induced by oxybutynin: presentation of two cases. Clin Drug Investig 2006; 26 (10): 603-6 (Pubitemid 44411336)
63. Nye AM, Clinard VB, Barnes CL. Medication nonadherence secondary to drug-induced memory loss. Consult Pharm 2010 Feb; 25 (2): 117-21
64. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol 2003 May; 60 (5): 771-3 (Pubitemid 36569899)
65. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use.NEngl J Med 2003 Dec 4; 349 (23): 2274-5 (Pubitemid 37485153)
66. Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use [abstract]. Am J Obstet Gynecol 2007 Aug; 197 (2): e8 (Pubitemid 47198192)
67. Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 2008; 27 (4): 315-8 (Pubitemid 351656403)
68. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005 Nov; 96 (7): 1055-62 (Pubitemid 41531414)
69. Dean M, Rzhetsky A, Allikmets R. The human ATPbinding cassette (ABC) transporter superfamily. Genome Res 2001 Jul; 11 (7): 1156-66 (Pubitemid 32677289)
70. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004; 10 (12): 1295-312 (Pubitemid 38559749)
71. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2003; 2 Suppl. 1: S1-8
72. Geyer J, Gavrilova O, Petzinger E. The role of Pglycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009 Jul; 37 (7): 1371-4
73. Geyer J, Gavrilova O, Schwantes U. Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin. UroToday Int J 2010; 3 (1): doi:10.3834/uij.1944-5784.2010.02.12
74. Sandage B, Sabounjian L, Shipley J, et al. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol 2006 Jul; 46 (7): 776-84 (Pubitemid 43882801)
75. Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007 Feb; 24 (2): 318-27 (Pubitemid 46072191)
76. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007 Jan 26; 315 (5811): 525-8 (Pubitemid 46175758)
77. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allelewith P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 Mar 28; 97 (7): 3473-8 (Pubitemid 30183327)
78. Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics 2007 May; 62 (5): 15-24
79. Abdel-Rahman A, Shetty AK, Abou-Donia MB. Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol Dis 2002 Aug; 10 (3): 306-26 (Pubitemid 35217583)
80. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001 Jan 5; 888 (1): 117-27 (Pubitemid 32056268)
81. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007 Jul; 28 (7): 977-86 (Pubitemid 46635913)
82. Bronge L, Wahlund LO. White matter lesions in dementia: an MRI study on blood-brain barrier dysfunction. Dement Geriatr Cogn Disord 2000 Sep-Oct; 11 (5): 263-7 (Pubitemid 30665928)
83. Starr JM, Wardlaw J, Ferguson K, et al. Increased bloodbrain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003 Jan; 74 (1): 70-6 (Pubitemid 36069039)
84. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003 Dec; 9 (6): 540-9 (Pubitemid 37479401)
85. Bennett J, Basivireddy J, Kollar A, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010 Dec 15; 229 (1-2): 180-91
86. Borges N, Shi F, Azevedo I, et al. Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs. Eur J Pharmacol 1994 Oct 14; 269 (2): 243-8
87. Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996 Nov; 142 (1): 14-28 (Pubitemid 26381377)
88. Black KL, Yin D, Ong JM, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008 Sep 16; 1230: 290-302
89. Robinson PJ. Measurement of blood-brain barrier permeability. Clin Exp Pharmacol Physiol 1990 Dec; 17 (12): 829-40
90. Oka T, Nakano K, Kirimoto T, et al. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Jpn J Pharmacol 2001 Sep; 87 (1): 27-33
91. Sugiyama T, Park YC, Kurita T. Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol Res 1999; 27: 393-5 (Pubitemid 29526147)
92. Suzuki M, Noguchi Y, Okutsu H, et al. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007 Feb 28; 557 (2-3): 154-8 (Pubitemid 46186296)
93. Cappon GD, Bush B, Newgreen D, et al. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. Eur J Pharmacol 2008 Jan 28; 579 (1-3): 225-8
94. McLeod-Flynn L, Reid L. Center for Drug Evaluation and Research pharmacology review: trospium chloride [application number 21-595]. Silver Spring (MD): Department of Health and Human Service, Public Health Service, Food and Drug Administration, 2004
95. Feng B, Mills JB, Davidson RE, et al. In vitro Pglycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008 Feb; 36 (2): 268-75 (Pubitemid 351185738)
96. Turvey CL, Schultz S, Arndt S, et al. Memory complaint in a community sample aged 70 and older. J Am Geriatr Soc 2000 Nov; 48 (11): 1435-41
97. Demers M, Rouleau I, Scherzer P, et al. Impact of the cognitive status on the memory complaints inMS patients. Can J Neurol Sci 2011 Sep; 38 (5): 728-33
98. Slavin MJ, Brodaty H, Kochan NA, et al. Prevalence and predictors of 'subjective cognitive complaints' in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry 2010 Aug; 18 (8): 701-10
99. Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009 Nov; 8 (6): 615-26
100. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. EurUrol 2006Aug; 50 (2): 317-26 (Pubitemid 44038078)
101. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005 Feb; 173 (2): 493-8
102. HerbergK, Fusgen I. Effect of trospiumchloride, oxybutynin- HCL and propiverin-HCL on traffic related performance with respect to safety. Geriat Forsch 1997; 7 (2): 77-83 (Pubitemid 27521485)
103. Herberg K. Everyday life safety and road safety after treatment with drugs against incontinence: Recent studies on the safety potential of urologic anticholinergics. Die Medizinische Welt 1999; 50 (4-5): 217-22 (Pubitemid 29262188)
104. Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or =50 years. BJU Int 2005 Feb; 95 (3): 346-9 (Pubitemid 40283121)
105. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004 Dec; 5 (6): 423-6
106. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47 (4): 337-43 (Pubitemid 24363337)
107. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003 Aug; 54 (2): 235-8 (Pubitemid 36909622)